Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1113 - Stereotyped BCR Subset #8 in Chinese CLL: Molecular Genetics, Clinical Behaviour, and Prognosis

    Primary Author / Presenter(s)

  • TQ

    Tong-lu Qiu, MD

    Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
    Nanjing, Jiangsu, China (People's Republic)

    • Co-Author(s)

  • Yi Xia, MD

    Attending Physician, Department of Hematology
    Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
    Nanjing, Jiangsu, China (People's Republic)

  • SY

    Shuhua Yi, PhD

    1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
    Tianjin, Tianjin, China (People's Republic)

  • CQ

    Chun Qiao, PhD

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
    Nanjing, China (People's Republic)

  • Huayuan Zhu, MD

    Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
    Nanjing, Jiangsu, China (People's Republic)

  • YY

    Yuting Yan, PhD

    China
    Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China (People's Republic)

  • Wei Xu, MD

    1. Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
    Nanjing, Jiangsu, China (People's Republic)

  • Lugui Qiu, PhD

    Professor & Director, Department of Lymphoma & Myeloma
    1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
    Tianjin, Tianjin, China (People's Republic)

  • JL

    Jianyong Li, MD

    Chief of Hematology department
    Department of Hematology, Key Laboratory of Nanjing Medical University, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China
    Nanjing, Jiangsu, China (People's Republic)